Avistone is a biotechnology company that develops innovative drugs. The company's core team consists of experienced professionals with expertise in early drug development, clinical study, industrial production, and commercial development.

Avistone

Avistone is an oncology company focused on developing innovative therapies for patients with significant unmet medical needs globally.  Avistone has an extensive pipeline of targeted therapies including two clinical-stage drug candidates and several ongoing programs in the pre-clinical development stage.  The Company’s lead asset is PLB1001, a small-molecule inhibitor that targets MET tyrosine kinase activity, including aberrant activity observed with METexon14 skipping (genetic) alterations in NSCLC tumors and in other solid tumors.  The company's second clinical asset is PLB1004, a potent inhibitor of EGFR tyrosine kinases (TKI), including aberrant activity observed with EGFR exon20 insertion (genetic) mutations in NSCLC tumors.  

COM:AVISTONEBIO

Avistone

Financials Not Available